enGene Therapeutics Inc. ENGN
Set alert
At close · Oct 30
After hours · Oct 30, 7:49 PM ET
- YTD
- -83.06%
- 1 year
- -78.02%
- Open
- 1.53
- Prev close
- 1.53
- Mkt cap
- 102.53M
- Vol
- 1.20M
- Avg vol
- 743.97K
- EPS
- -2.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.46
- High
- 1.55
- Forward P/E
- -3.53
- Beta
- -0.76
- Short ratio
- 11.39
- Inst. own
- 83.23%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 8.10
- 200-d avg
- 10.01
- 1y target
- 27.00
News
2 weeks ago marketbeat.com
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
enGene NASDAQ: ENGN used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse,…
2 weeks ago seekingalpha.com
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript
2 weeks ago businesswire.com
enGene to Host KOL Webinar on October 15, 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a…
1 month ago seekingalpha.com
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago seekingalpha.com
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market
enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite pipeline and execution risks. ENGN's lead asset, detalimogene voraplasmid, faces FDA approval risk…
-
1 month ago benzinga.com
Citizens Reiterates Market Perform on enGene Therapeuticsto Market Perform
Citizens analyst Silvan Turkcan reiterates enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Market Perform.
-
1 month ago benzinga.com
enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 17.54 percent increase over losses of…
1 month ago businesswire.com
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results…
2 months ago businesswire.com
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will…
2 months ago defenseworld.net
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies…
2 months ago marketbeat.com
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a…
2 months ago seekingalpha.com
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
2 months ago businesswire.com
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a…
-
3 months ago benzinga.com
EnGene Therapeutics Appoints Michael Heffernan Board Chairman, Effective Immediately, Succeeding Richard Glickman
enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential
3 months ago businesswire.com
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of…
3 months ago globenewswire.com
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to…
4 months ago benzinga.com
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzinga's analyst ratings page.
-
4 months ago benzinga.com
Morgan Stanley Downgrades enGene Therapeutics to Underweight
Morgan Stanley analyst Judah Frommer downgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Underweight.
4 months ago benzinga.com
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday
Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey.…
-
4 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $6 to $4.
-
4 months ago benzinga.com
EnGene Therapeutics Implements Workforce Reduction Of About 50% In June 2026; CFO Ryan Daws To Depart From Co, Effective July 15, 202
Recent Corporate UpdatesReduction in Force and Executive Departures: In June 2026, enGene implemented a plan to reduce its workforce by approximately 50% to streamline operations and preserve cash.…
-
4 months ago benzinga.com
enGene Holdings Q2 EPS $(0.43) Beats $(0.47) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.47) by 8.51 percent. This is a 15.69 percent increase over losses of…
4 months ago businesswire.com
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced its financial results for…
4 months ago prnewswire.com
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics…
4 months ago prnewswire.com
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics…
4 months ago seekingalpha.com
EnGene Therapeutics: The Selloff Creates An Opportunity
enGene Therapeutics is rated Buy, trading below its $4.66/share cash floor despite weak Phase 2 data for its sole asset, detalimogene voraplasmid. ENGN's therapy showed only a 25% 12-month complete…
5 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ: ENGN). Such investors are advised…
5 months ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. (“Engene” or the “Company”) (NASDAQ: ENGN). Such investors are…
5 months ago businesswire.com
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $ENGN--ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm.
5 months ago benzinga.com
Why Is enGene Therapeutics Stock Falling Friday?
enGene stock sinks after Phase 2 bladder cancer trial shows durability concerns. Analysts slash price forecasts as the sell-off intensifies.
-
5 months ago benzinga.com
Citizens Downgrades enGene Therapeutics to Market Perform
Citizens analyst Silvan Turkcan downgrades enGene Therapeutics (NASDAQ:ENGN) from Market Outperform to Market Perform.
-
5 months ago benzinga.com
Wells Fargo Downgrades enGene Therapeutics to Equal-Weight, Lowers Price Target to $2
Wells Fargo analyst Yanan Zhu downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Equal-Weight and lowers the price target from $25 to $2.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $6
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $25 to $6.
-
5 months ago benzinga.com
Piper Sandler Downgrades enGene Therapeutics to Neutral, Lowers Price Target to $4
Piper Sandler analyst Allison Bratzel downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Neutral and lowers the price target from $7 to $4.
5 months ago benzinga.com
Dow Dips 350 Points; US Foods Posts Downbeat Earnings
Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US Foods reports lower Q1 earnings and sales. Agilon Health, Aaon, and Rackspace Technology see gains…
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
5 months ago benzinga.com
US Stocks Mixed; Dow Falls Over 100 Points
US stocks higher Thursday morning, Dow down 0.28%, Nasdaq up 0.50%, S&P 500 up 0.07%. Tech sector up 1.1%, energy sector down 2.8%. McDonald's reports strong earnings and sales.
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
6 months ago benzinga.com
WBB Securities Initiates Coverage On enGene Therapeutics with Buy Rating, Announces Price Target of $21.5
WBB Securities analyst Karen Sterling initiates coverage on enGene Therapeutics (NASDAQ:ENGN) with a Buy rating and announces Price Target of $21.5.
-
6 months ago benzinga.com
enGene Holdings To Change Its Corporate Name To enGene Therapeutics Effective April 8
Name change reflects transition towards potential commercial organization in 2027Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026enGene Therapeutics Inc. (formerly,…
-
7 months ago benzinga.com
Oppenheimer Maintains Outperform on enGene Holdings, Lowers Price Target to $30
Oppenheimer analyst Leland Gershell maintains enGene Holdings (NASDAQ:ENGN) with a Outperform and lowers the price target from $33 to $30.
-
7 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on enGene Holdings, Maintains $25 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates enGene Holdings (NASDAQ:ENGN) with a Buy and maintains $25 price target.
-
7 months ago benzinga.com
enGene Holdings Q1 EPS $(0.44) Beats $(0.58) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.58) by 24.53 percent. This is a 8.33 percent increase over losses of…
-
10 months ago benzinga.com
enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.3 percent. This is a 114.71 percent decrease over losses of…
-
11 months ago benzinga.com
enGene Holdings Says FDA Selects Detalimogene Voraplasmid To Participate In Chemistry, Manufacturing, And Controls Development And Readiness Pilot Program
enGene one of nine companies awarded CDRP per yearProgram aims to support CMC development of products with expedited clinical development timeframes and provide patients with earlier access to these…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
11 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
11 months ago benzinga.com
Morgan Stanley Maintains Overweight on enGene Holdings, Raises Price Target to $19
Morgan Stanley analyst Jeffrey Hung maintains enGene Holdings (NASDAQ:ENGN) with a Overweight and raises the price target from $18 to $19.
-
11 months ago benzinga.com
Oppenheimer Reiterates Outperform on enGene Holdings, Raises Price Target to $33
Oppenheimer analyst Leland Gershell reiterates enGene Holdings (NASDAQ:ENGN) with a Outperform and raises the price target from $30 to $33.
-
11 months ago benzinga.com
UBS Maintains Neutral on enGene Holdings, Raises Price Target to $10
UBS analyst Colin Bristow maintains enGene Holdings (NASDAQ:ENGN) with a Neutral and raises the price target from $4 to $10.